<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00187122</url>
  </required_header>
  <id_info>
    <org_study_id>NHL13</org_study_id>
    <nct_id>NCT00187122</nct_id>
  </id_info>
  <brief_title>Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma</brief_title>
  <official_title>Treatment for Newly Diagnosed Patients With Stage III/IV Non-Hodgkin Lymphoma-Study XIII (A Therapeutic Pilot Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine if it is feasible to administer an&#xD;
      intensified, multi-agent chemotherapy regimen for children with stage III and IV non-Hodgkin&#xD;
      lymphoma and to find out what the toxicities are.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective of this research study is to determine the toxicity and feasibility of&#xD;
      administration of an intensified, multi-agent chemotherapy regimen for children with stages&#xD;
      III and IV non-Hodgkin lymphoma (NHL), lymphoblastic histiotype. The planned pilot therapy&#xD;
      includes major modifications of our best previous treatments for patients with T-cell acute&#xD;
      lymphoblastic leukemia (ALL) that may improve the disease-free survival of these children and&#xD;
      adolescents. Ultimately, it is intended to propose this therapy for further evaluation in the&#xD;
      setting of a patient population large enough to evaluate its efficacy.&#xD;
&#xD;
      Secondary objectives are:&#xD;
&#xD;
        -  To determine the toxicity of high-dose methotrexate (HDMTX) given prior to the&#xD;
           induction/consolidation phase of therapy and of repeated induction treatment (weeks&#xD;
           16-21) in patients with advanced stage NHL, lymphoblastic histiotype.&#xD;
&#xD;
        -  To determine the toxicity and feasibility of administration of continuation therapy&#xD;
           which include additional drug pairs not used in the St. Jude Total XI-ALL study.&#xD;
&#xD;
        -  To estimate the complete response (CR) rate and event-free survival (EFS) in children&#xD;
           with stage III/IV lymphoblastic NHL after treatment with this intensified multiagent&#xD;
           chemotherapy. Pooling of data from this study with that gained from treatment of&#xD;
           patients with T-ALL on the Total XIII and XIII B studies, with appropriate&#xD;
           stratification, will facilitate this aim.&#xD;
&#xD;
        -  To compare plasma and cerebrospinal fluid concentrations of VP-16 after 1 hour of&#xD;
           administration. The data obtained here will be pooled for analysis with that from Total&#xD;
           XIII and Total XIII B studies&#xD;
&#xD;
        -  To assess serially whether the frequency of specific HPRT mutations in are related to&#xD;
           cumulative dose of etoposide, or plasma AUC of etoposide, etoposide catechol, or both&#xD;
&#xD;
        -  To assess the degree of bone marrow infiltration at the time of diagnosis and serially&#xD;
           during remission using and comparing morphologic, immunologic and molecular methods. In&#xD;
           the absence of morphologically detected tumor cells, we will estimate the frequency of&#xD;
           minimal residual disease (MRD) during remission using immunologic and molecular methods.&#xD;
           The data obtained here will be pooled for analysis with that obtained from T-cell ALL&#xD;
           cases treated on Total XIII and Total XIII B ALL studies.&#xD;
&#xD;
        -  Because similar studies are being conducted for patients with T-ALL on the Total XIII&#xD;
           and Total XIII B ALL studies, we will pool data from the present study with that from&#xD;
           T-cell ALL cases treated on Total XIII and Total XIII B ALL studies and correlate&#xD;
           detection of lymphoblasts in bone marrow or cerebrospinal fluid (CSF) with subsequent&#xD;
           clinical course (complete remission duration).&#xD;
&#xD;
        -  To evaluate the sensitivity of neoplastic cells at diagnosis to anticancer drugs. This&#xD;
           evaluation will be limited to patients with bone marrow involvement or viable tumor&#xD;
           samples at diagnosis. Information obtained from this aim will complement that obtained&#xD;
           from patients with T-ALL in the Total XIII and Total XIII B ALL studies.&#xD;
&#xD;
      Details of Treatment Plan:&#xD;
&#xD;
      Pre-Induction Chemotherapy&#xD;
&#xD;
      Methotrexate 200 mg/m2/hr IV push, then 800 mg/m2 IV over 24 hours&#xD;
&#xD;
      Induction&#xD;
&#xD;
      Induction Chemotherapy uses several chemotherapy drugs to kill cancer cells in the body and&#xD;
      lasts 6 to 8 weeks.&#xD;
&#xD;
      Prednisone 40 mg/m2/day PO, days 1-29, Vincristine 1.5 mg/m2/week IV, days 1, 8, 15, 22,&#xD;
      Daunomycin 25 mg/m2/week IV, days 1, 8, L-asparaginase 10,000 Units/m2 IM days 2, 4, 6, and 8&#xD;
      Etoposide 300 mg/m2 IV Days 22, 25, 29, Cytarabine 300 mg/m2 IV Days 22, 25, 29 For infants&#xD;
      less than 12 months of age, Vincristine dosage is 0.05 mg/kg/dose. CNS Therapy&#xD;
&#xD;
      All patients will receive triple IT therapy on days 1, 22, and 43. Patients with known CNS&#xD;
      disease will receive additional IT treatments until 2 consecutive CSF studies are normal.&#xD;
      Children with cranial nerve palsies will receive local irradiation to the base of the skull.&#xD;
&#xD;
      Consolidation:&#xD;
&#xD;
      HDMTX 2 g/m2 days 44 and 51. Mercaptopurine 75 mg/m2 PO daily, for 14 days. ITMHA will be&#xD;
      given into spinal fluid (IT) the day before first HDMTX dose.&#xD;
&#xD;
      Continuation&#xD;
&#xD;
      Continuation: Continuation therapy lasts 120 weeks. The following drugs will be given in&#xD;
      different two-drug combinations during this treatment:&#xD;
&#xD;
      Weeks:&#xD;
&#xD;
      1 VP-16 + Cyclo, 2* 6-MP + MTX, 3 MTX + Ara-C, 4 Dex + VCR, 5 VP-16 + Cyclo, 6 6-MP + HDMTX,&#xD;
      7 VP-16 + Ara-C, 8 Dex + VCR 9 VP-16 + Cyclo, 10 6-MP + MTX, 11 MTX + Ara-C, 12 Dex + VCR, 13&#xD;
      VP-16 + Cyclo, 14* 6-MP + HDMTX, 15 VP-16 + Ara-C&#xD;
&#xD;
      IT MHA (MTX, hydrocortisone, Ara-C, dose age dependent, given one day before HDMTX. IT MHA&#xD;
      (every 4 weeks) for patients with CNS 2 or 3 status. Reinduction therapy (same as initial&#xD;
      induction treatment, except that only one dose of VP-16/ara-C will be given on day 22) will&#xD;
      be given from weeks 16 to 21.&#xD;
&#xD;
      Dosages, Schedules and Routes VP-16: 300 mg/m2 IV over 1 hour; once a week, Cyclophosphamide:&#xD;
      300 mg/m2 IV push; once a week, Mercaptopurine (6-MP): 75 mg/m2 PO; daily x 7, Methotrexate&#xD;
      (MTX): 40 mg/m2 IM or IV once a week; only IM after CNS radiation, Cytarabine (Ara-C) 300&#xD;
      mg/M2 IV push; once a week, Dexamethasone (Dex): 8 mg/m2 PO; in 3 divided doses daily x 7,&#xD;
      Vincristine (VCR) 1.5 mg/m2 IV; once a week (max 2 mg) L-Asparaginase, (L-ASP): 10,000 U/m2&#xD;
      IM; every 4 weeks x 9, HDMTX: 2 g/m2 IV over 2 hours; every 8 weeks x 7 (same leucovorin&#xD;
      rescue as used in consolidation phase)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1993</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine toxicity and feasibility of intensified multiagent chemotherapy and high dose methotrexate.</measure>
    <time_frame>Within first 30 days following pre-induction chemotherapy</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Lymphoblastic Lymphoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>See Detailed Description section for description of treatment plan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>See Detailed Description section for description of treatment plan.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Oncovin®, Vincasar Pfs®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>See Detailed Description section for description of treatment plan.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunomycin</intervention_name>
    <description>See Detailed Description section for description of treatment plan.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cerubidine®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Asparaginase</intervention_name>
    <description>See Detailed Description section for description of treatment plan.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Elspar®, Kidrolase®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>See Detailed Description section for description of treatment plan.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cytosar-U®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>See Detailed Description section for description of treatment plan.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Rheumatrex®, TrexallTM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <description>See Detailed Description section for description of treatment plan.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Purinethol ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>See Detailed Description section for description of treatment plan.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Toposar®, VePesid®, Etopophos®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>See Detailed Description section for description of treatment plan.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cytoxan®, Neosar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>See Detailed Description section for description of treatment plan.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Deltasone®, Liquid Pred®, Meticorten®, Orasone®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>See Detailed Description section for description of treatment plan.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Decadron, Diodex, Hexadrol, Maxidex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stage III or IV Lymphoblastic Lymphoma&#xD;
&#xD;
          -  One week or less of prior therapy, only to include steroids, vinca alkaloids, and&#xD;
             emergency radiation therapy to the mediastinum in those with severe respiratory.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patients with superior vena cava syndrome, significant compression of the trachea&#xD;
             requiring more than 40% oxygen or having significant dyspnea at normal activity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raul C. Ribeiro, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>April 21, 2008</last_update_submitted>
  <last_update_submitted_qc>April 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>Raul C. Ribeiro, M.D./Principal Investigator</name_title>
    <organization>St.Jude Children's Research Hospital</organization>
  </responsible_party>
  <keyword>Non-Hodgkin</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

